NCT05626400 2022-11-25Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLHebei Senlang Biotechnology Inc., Ltd.Phase NA Recruiting100 enrolled